Late-Life Gene Therapy Boosts Lifespan in Mice by 20%

Key Takeaways

• AAV‑mediated FGF21 gene therapy extended median mouse lifespan by 20%.
• Treated mice lost weight without reducing food intake, indicating higher energy expenditure.
• Multiple organs showed reduced inflammation, fibrosis, and improved mitochondrial function.
• Cognitive performance in aged mice matched that of young controls.
• Bone health remained unchanged despite prolonged high FGF21 levels.

Pulse Analysis

Metabolic dysfunction sits at the heart of age‑related decline, driving fat accumulation, insulin resistance, and reduced cellular energy efficiency. While lifestyle interventions such as exercise and caloric restriction can mitigate these effects, adherence is notoriously difficult, prompting researchers to seek pharmacologic mimetics. Fibroblast growth factor 21 (FGF21) has emerged as a potent endocrine regulator of glucose and lipid metabolism, and its therapeutic promise has spurred multiple drug development programs. By harnessing an adeno‑associated virus (AAV) to embed the FGF21 gene directly into skeletal muscle, scientists aim to create a self‑sustaining source of the hormone that bypasses the need for repeated dosing.

The Barcelona team injected AAV‑FGF21 into the leg muscles of 13‑month‑old male mice, a stage equivalent to late middle age in humans. Serum FGF21 remained elevated for months, driving a cascade of systemic benefits: mice shed excess weight without eating less, displayed superior glucose tolerance, enhanced treadmill performance, and showed cognitive scores comparable to two‑month‑old controls. Histological analysis revealed smaller adipocytes, reduced inflammatory markers, and restored mitochondrial DNA content across liver, kidney, heart, and brain. Most strikingly, median lifespan rose from 28 to 34 months, a 20 % gain achieved with a single treatment.

These findings position muscle‑restricted FGF21 gene therapy as a viable candidate for human aging interventions, especially as the platform advances toward clinical trials with Kriya Therapeutics. The study also alleviates earlier safety concerns; despite chronic hormone elevation, bone turnover markers remained stable, suggesting adult‑onset expression avoids the bone loss seen in lifelong transgenic models. If similar healthspan extensions translate to patients, the market potential spans metabolic disease, neurodegeneration, and longevity therapeutics, attracting biotech investors seeking next‑generation, one‑time gene‑based solutions.